Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine + rituximab versus standard rituximab-chemotherapy for previously untreated indolent non-Hodgkin lymphoma or mantle cell lymphoma
ACTRN12610000445077Phase 3Active, not recruiting
- Sponsor
- Cephalon, Inc.
- Start
- Jun 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of bendamustine and rituximab in non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL) (2 arms), sponsored by Cephalon, Inc. Primary endpoint: Complete response rate. Started Jun 2009; status: active, not recruiting.
02
Drugs
bendamustinerituximab
03
Conditions
non-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ACTRN12610000445077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000445077.